Statins as a Therapeutic Approach for the Treatment of Pseudoxanthoma Elasticum Patients: Evaluation of the Spectrum Efficacy of Atorvastatin In Vitro

Cells. 2021 Feb 19;10(2):442. doi: 10.3390/cells10020442.

Abstract

Pseudoxanthoma elasticum (PXE) is an autosomal recessive disorder caused by mutations in the ATP-binding cassette sub-family C member 6 gene. Our previous studies revealed that PXE might be associated with premature aging. Treatment with statins showed positive effects not only for PXE but also for other diseases associated with premature aging like Hutchinson-Gilford progeria syndrome. Nevertheless, the molecular mechanisms in the case of PXE remain unclear. Thus, this study was performed to evaluate the efficiency of atorvastatin by analyzing key characteristics of the PXE phenotype in primary human dermal fibroblasts of PXE patients. Our data indicate that an atorvastatin treatment has a positive effect, especially on factors associated with cholesterol biosynthesis and prenylation processes, whereas the effect on age- and calcification-related factors was less pronounced.

Keywords: atorvastatin; cholesterol biosynthesis; pseudoxanthoma elasticum.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Atorvastatin / therapeutic use*
  • Female
  • Gene Expression / genetics*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Male
  • Middle Aged
  • Pseudoxanthoma Elasticum / drug therapy*

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Atorvastatin